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Abstract. The use of 5-aminolevulinic acid and its esters to 
induce endogenous porphyrins for the purpose of detection of 
epithelial cancers is being studied extensively in many centr.es 
around the world. The challenge is to prepare an efficacious 
formulation for the purpose of cancer detection. Photodynamic 
diagnosis of cancer using 5-aminolevulinic acid (ALA) and 
its ester derivatives is being actively investigated. In this 
study, we compared ALA with ALA methyl ester (AME) 
derivative in terms of PplX fluorescence intensity in in vitro 
and in vivo systems of bladder carcinoma. For the in vivo 
system consisting of RT112 xenografts, the modes of drug 
administration compared were intravenous administration and 
topical application. The Karl Storz fluorescence endoscopy 
system was used to obtain macroscopic fluorescence images. 
The macroscopic images were further analysed for fluorescence 
intensity distribution. For the intravenous administration, over 
all time points studied (1, 3, 6 h), AME-PpIX fluorescence 
was lower than ALA-PplX fluorescence and was cleared at 
a faster rate than the ALA-PplX when administered intra-
venously. Topical application with two different polymers, 
Gantrez and Polyvinyl pyrrolidone (PVP) which are fast 
releasing polymers was found to be comparable in inducing 
PpIX fluorescence. Topical AME-PplX fluorescence was 
found to be comparable with ALA-PpIX fluorescence. The 
results of this study suggest that the AME can also be used as 
a good diagnostic agent. 
Introduction 
Bladder cancer is one of the most prevalent malignant 
diseases in the world (1). In Singapore, it is the 9th most 
common type of malignancy. It has been reported that 75-80% 
of malignancies is superficial in nature and the chances of 
recurrence after first treatment in these malignancies are 70% 
(2). Early diagnosis of dysplasia and urothelial tumours plays 
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an important role in prognosis of the disease. The use of endo-
genous protoporphyrin IX (PplX) as a photosensitizer to 
diagnose certain superficial cancers is under extensive study 
in many centres around the world. This is because it is a non-
invasive technique. Endogenous PpIX can be induced by the 
administration of excess 5-aminolevlinic acid (ALA) or its 
esterified analogues. ALA is a precursor in the heme bio-
synthetic pathway of nucleated cells. It is metabolized by 
certain endogenous enzymes to produce PpIX. PpIX is a photo-
sensitive intermediate by-product in the heme biosynthetic 
pathway (3). Along with PpIX there are other porphyrin 
species such as heptaporphyrin, coproprophyrin, and uro-
pophyrin (13,14). Survival of mammalian cells is crucially 
dependent upon the biosynthesis and metabolism of porphyrins 
(4). PpIX being the immediate precursor of heme will also be 
synthesized in equal amounts. However, a tight feedback loop 
control ensures that only a scarce amount of PpIX is left at 
any one time (5). Accumulation of the endogenous porphyrins 
only happens under abnormal conditions such as in malignant 
or pre-malignant cell transformation. PplX preferentially 
accumulates in tumour cells due to changes in th.e activity of 
two main enzymes, porphobilinogen deaminase (PBG) and 
ferrochelatase (FC) (6-8). In tumour cells, while the activity 
of PBG is increased, the activity of FC is decreased resulting 
in the build up of PpIX. In normal cells, FC catalyses the 
conversion of photosensitive PpIX to heme, which is not 
photosensitive. It chelates the Fe2+ into the porphyrin ring 
structure. The administration of excess exogenous ALA or 
various esterified analogues of ALA can also induce the excess 
production of PpIX (topically or intravenously). While ALA 
is hydrophilic, which is a limitation as it restricts its penetration 
through cellular membranes; its ester derivatives have been 
developed to be of increased lipophilicity. In our study we 
have compared AME with ALA. Increased transmembrane 
access into the cell, large amounts of ALA can be generated 
inside the cell due to the abundance of non-specific intracellular 
esterases in majority of the cells (15). Different esterified 
analogues behave differently in cells. The cytotoxicity and 
phototoxicity vary among these esters. Though the esters 
enter the cell at a faster rate, they need to be cleaved in order 
to function in the heme biosynthetic pathway. However, the 
mechanism by which the ALA enters the cells is transported 
across the membrane via peptide transporters and the transport 
is electrogenic and coupled to H+ transport (6,16). 
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PpIX is a well-known photosensitizer that yields sufficient 
singlet oxygen when activated by light of appropriate wave-
length and intensity. ALA is already in use in many centres for 
photodynamic diagnosis ~PDD) and photodynamic therapy 
(PDT) in various superficial diseases such as actinic keratosis, 
basal cell carcinoma and squamous cell carcinoma. ALA 
induced PpIX is also highly fluorescent. Upon activation with 
blue/violet light, PpIX fluoresces in red. ALA is also used for 
the detection of neoplastic urothelial lesions, early stage lung 
cancer, cervical dysplasia and laryngeal neoplasm. Most 
studies have been done on applications to the skin. It was 
observed that the skin overlaying the tumours, which looks 
normal, constitutes a much lower barrier for ALA penetration 
than the skin overlaying healthy tissues. It was also found 
that the ALA induces more PpIX fluorescence than certain of 
its esters do. Systemic uptake is also reported to be higher 
resulting in high accumulation of PpIX in other vital organs 
such as the liver, gut and skin. These studies were compared 
with intravenous or intraperitoneal administrations of ALA 
(9-I2). AME-PDT is currently being studied in basal cell 
carcinomas in humans. Very few studies have reported the 
use of AME for cancer detection due to the seemingly low 
production of PplX in vivo. 
One of the aims of this study was to compare the uptake 
and retention kinetic of ALA and AME in bladder cancer 
cells in vitro and in vivo. We went on to conduct this study by 
using topical applications of ALA and AME and intravenous 
administration. With the use of macroscopic fluorescence 
imaging of endogenous PpIX, the optimal selectivity between 
tumour and normal regions was determined. For the topical 
application two fast acting polymers Gantrez and Polyvinyl 
pyrrolidone (PVP) were compared, these are currently being 
studied for rapid drug delivery and transdermal films. Gantrez 
is a synthetic copolymer of methylvinyl ether and maleic 
anhydride. It has several applications such as transdermal 
films and carriers for mucosa! applications of the oral cavity. 
PVP is also being extensively studied in area of transdermal 
films (I7). 
Materials and methods 
In vitro cellular uptake studies. RT112 is a grade II (poorly 
differentiated) human bladder carcinoma cell line (ATCC). 
It was a kind gift from Clinical Research Centre, National 
University of Singapore. The cells were grown in culture 
medium RPMI I640 supplemented with 10% fetal bovine 
serum (FBS; Hyclone, Logan, UT), IX L-glutamine, 100 units/ 
ml penicillin and streptomycin (Gibco) and IX sodium 
pyruvate in an atmosphere of 5% C02 at 37°C. Confluent 
cells were trypsinized with 0.05% Trypsin-EDTA (Gibco) 
and seeded onto 100 mm petri dishes (l.5xl06 cells/dish) 
and left to settle and attach overnight. The culture medium 
was removed and the cells were washed twice with IX PBS. 
The petri dishes were divided into two groups. They were 
incubated with I5 mM ALA and I5 mM AME in culture 
medium without serum for 30 min. The cells were then washed 
with IX PBS. Fresh medium without serum was added to the 
dishes and incubated at 37°C with 5% C02 for I, 3, 6, 9 and 
24 h. At each time point the cells were washed with IX PBS, 
scraped and incubated in perchloric acid and methanol mixture 
(I:I) for I5 min. ALA and AME induced PpIX was detected 
using the spectrofluorophotometer RF-530I PC (Shimadzu). 
Excitation was set at 400 nm and the emission spectrum range 
was set at 500 to 700 nm. 
Tumour model. RTI I2 cells were grown in culture medium 
as for the in vitro studies. Once confluent they were washed 
with IX phosphate buffered saline and trypsinized with 0.05% 
Trypsin-EDTA (Gibco). The cells were then re-suspended 
in IX Hanks balanced salt solution. Male Balb/c nude mice, 
6-8 weeks old, about 20-25 g were obtained from Animal 
Resource Centre of Australia. The trypsinized cells (l.5xIQ6) 
were implanted subcutaneously into the flanks of the nude 
mice. The mice were housed in micro-isolator cages (5 per 
cage) fed with filtered air through air vents. Their food, water 
and bedding were sterilized. The tumour was allowed to grow 
over the next 7-10 days to a size of 5-8 mm in diameter. 
ALA/AME topical applications. For the Gantrez topical 1 
application, ALA/AME were dissolved in poly (methyl vinyl'1 
.~ 
ether/maleic anhydride (Gantrez, ISP, USA)/poly (meth)' 
acrylates (Eudragit, Rohm Pharma, Germany)/alcohol 
solution. For the PVP, ALA and AME were dissolved in. 
polyvinyl-pyrrolidone (Plasdone, ISP, USA)/alcohol solution. 
A concentration of 2.5 mg/cm2 of ALA and AME for both 
formulations of topical application was prepared. The solutio 
was then poured onto a calculated area of polythene sheets 
and air dried to form films. The films were cut into 1.5 cm 
pieces and sealed in bags and stored for further use. Botli 
formulations have muco-adhesive properties. · 
Animal experiments. Six groups of balb/c nude mice wer 
used. Group I was used for the intravenous administration o 
ALA. Group 2 was used for intravenous administration o 
AME. Group 3 was used for Gantrez ALA topical application 
Group 4 was used for Gantrez AME topical application. Grau 
5 was used for PVP ALA topical application. Finally group 
was used for (PVP) AME topical application. For topica 
application, 5 mice per group were used. The nude mic 
were anaesthetized with a cocktail of Hypnorm (0.3 I5 mg/ 
fentanyl citrate and 10 mg/ml flaunisone, Janssen), Dormic 
(5 mg/ml midazolam HCl, David Bull Laboratories) an 
deionised water (I:I:2). The skin overlaying the tumour wa 1 
carefully removed to expose the tumour. Extreme care wa 
taken to minimize bleeding as this can interfere with th 
imaging procedure. A white light image of the tumour wa 
obtained using the Karl Storz fluorescence endoscopy syste 
(FES). This is to help later in identifying the tumour and it 
margins when comparing with the fluorescence image. Th 
films were then applied on the tumour making sure that th. 
patch covered the tumour well and also part of the norm ' 
tissue surrounding the tumour. For the muco-adhesive films 
the patch was applied for 30 min and then removed. The are 
was rinsed well with 70% alcohol to remove any residual AL 
The tumour was imaged at different time points, post topica 
application, by the FES using filtered blue light at 460 nm. 
Intravenous administration. ALA/AME was dissolved i 
deionized water and the pH was adjusted to 6.5. The mic 
were administered with a dose of 250 mg/kg-body weight b 
r 
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Figure 1. PpIX fluorescence of ALA and AME treated RTI 12 cells. 
tail vein injections. Five animals were used for each time 
point. They were then kept in darkness. The mice were 
imaged at various time points, such as 1, 3 and 6 h. The skin 
overlaying the tumour was removed and the tumours were 
imaged using the FES. The mice were then sacrificed, the 
tumours were removed and snap frozen in liquid nitrogen and 
stored at -80°C for further analysis. 
Instrumentation. The system consists of a fluorescence 
detection unit, an illumination console, a video displaying 
and recording unit, and a computing system for image 
acquisition, display and processing. A 100 W xenon arc lamp 
(D-Light AF system, Karl Storz, Germany) is used for the 
white light illumination and the PpIX fluorescence excitation 
when filtered by a band pass filter (370-450 nm). The 
excitation power of the blue light at the endoscope tip is 
approximately 50 mw. Both of the light illumination and 
the observation of the tissue targeted are achieved via a 
modified endoscope equipped with a long pass (LP) filter 
(cut-off wavelength at 470 nm). The white light and ALA 
fluorescence imaging were achieved by a 3-chip colour CCD 
video camera (Tricam SL_PDD, Karl Storz, Germany) 
connected to the modified endoscope. 
Image analysis. The images thus obtained were analyzed 
using the image analysis software, Microlmage 4.0. Images 
obtained in blue light needed to be further processed to obtain 
normalized fluorescence intensity images. The processing 
involves cpntrast enhancement of the original image. This is 
followed by hue extraction where one extracts the fluorescence 
colour (red) that is needed. Following hue extraction, the 
thresholding and segmentation of the area of interest (AOI), 
which is the tumour in this case, was carried out. This gives 
us the red-black image. From this we obtained the relative 
intensity distribution over the tumour and the normal regions. 
Finally, the normalised intensity image, which is a ratio of the 
tumour fluorescence to the normal (blue) background, was 
obtained. 
Statistical analysis. Statistical analysis was done using the 
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Figure 2. (A), Normalized fluorescence intensity of tumour vs. normal as a 
function of time for IV ALA. (B), Normalized fluorescence intensity of 
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Figure 3. ALA induced PpIX fluorescence for Gantrez and PVP topical 
application. 
done by comparing means (ANOV A). The mean difference 
was found to be statistically significant (p<0.05). 
Results 
Using the spectrofluorophotometer, we measured the 
fluorescence intensity of ALA and AME induced PpIX in 
cells over time. Fig. 1 shows the ALA and AME induced 
PpIX fluorescence intensity of RTI 12 cells over time in vitro. 
While ALA induced PpIX fluorescence decreased after 9 h 
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Figure 4. AME induced PpIX fluorescence for Gantrez and PVP topical 
application. 
due to the PpIX being converted to heme, AME induced PpIX 
fluorescence continued to increase and peaked at around 24 h. 
This could be due to the fact that AME has to be cleaved before 
it enters the heme synthesis pathway. Fig. 2 shows the PpIX 
fluorescence intensity of RT112 tumours when administered 
with intravenous ALA and AME 2SO mg/kg respectively. It 
was observed that the tumour to normal differential was 
significantly high from the earliest time point 1 to 6 h. On the 
other hand AME induced PpIX fluorescence in the tumour 
was found to be high at 1 h but started to decline thereafter. 
By 6 h the tumour to normal differential was low. Fig. 3 
shows the PpIX fluorescence intensity of RT112 tumours 
when Gantrez ALA and PVP ALA were applied and imaged 
at the different time points. It was observed that the tumour 
to normal differential was increased significantly by 3 h and 
continued to increase even at 6 h. Fig. 4 shows the PpIX 
fluorescence intensity of RTl 12 tumours when Gantrez AME 
and PVP AME were applied and imaged at the different time 
points. This pattern was found to be similar to that of topical 
ALA applications. The only difference was that the AME 
induced PpIX fluorescence intensity seemed to be slightly 
higher especially at 6 h. Tumour to normal fluorescence ratio 
(TIN ratio) was calculated to better appreciate the fluorescence 
pattern found in the IV administration and the topical 
applications of the two drugs. Since both topical applications 
followed the same pattern, only one was chosen to be 
compared. The TIN ratio of topical PVP ALA and AME 
induced PpIX increased as a function of time between 1 to 6 h 
as seen in Fig. SA. However, the TIN ratio ofIV AME induced 
PpIX fluorescence decreased as a function of time between 1 
to 6 h while the IV ALA induced PpIX fluorescence increased 
as seen in Fig. SB. Fig. 6 shows a series of fluorescence images 
of different mice taken using the FES at different time points. 
The fluorescence pattern for IV and topical application is 
clearly visible. Fig. 6A-C denotes ALA IV; Fig. 6D and E 
denotes AME IV; Fig. 6G and H denotes PVP ALA; and 








Figure 5. (A), TIN fluorescence ratio of ALA and AME PVP induced PpIX. 
(B), TIN fluorescence ratio of ALA and AME IV induced PpIX. 
Discussion 
This study was done to investigate uptake and retention 
pharmacokinetics of ALA and AME in bladder cells in vitro. 
This pharmacokinetic profile in vitro was used to better. 
understand the difference between the in vitro and in vivo. 
Subsequently this tumour cell line was xenografted in nude, 
mice and the uptake kinetics studied in vivo. Then we wen 
on to compare the modes of administration of the drug. Intra-· 
venous administration of ALA for endogenous porphyrin based 
PDD and PDT, has been the normal mode of administration. 
AME is still being studied in many centres based on th 
rationale that esters are transported into cells at a faster rate. 
However, there are no in vivo studies of the intravenous' 
administration of AME in bladder cancer. In our investigations, 
we removed the skin overlaying the tumour to mimic epi-
thelial condition where the drug does not have to trave 
through the stratum corneum, sebacious glands, dermal papill 
etc. We detected that the intravenous ALA and AM . 
administration not only gives high fluorescence of tumour' 
but also that of normal distal organs such as the skin, normal 
liver and intestines from as early as 1 h post ALA and AME1 
administration, which is due to considerable amounts o 
circulating ALA inducing local PpIX. However, it was foun 
that the fluorescence intensity of tumour was reasonably high, 
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Figure 6. Fluorescence images captured with the FES. (A-C), ALA IV; (D-F), AME IV; (G-I), PVP ALA application; (J-L), PVP AME application. The tumour 
has been imaged with the surrounding tissue and skin. 
from 1 to 6 h post intravenous administration compared to 
adjacent normal tissue. On the contrary, the topical applications 
did not produce high fluorescence for either the tumour or 
normal at 1 h post application. Significant difference between 
tumour and normal was evident only at the 3-h time point. 
It is noteworthy that the fluorescence of normal tissue was 
lower than that of the normal tissue in intravenous 
application at the same time point. At 6 h the difference 
between tumour and normal is 4.4 times greater and statistically 
significant (p<0.05). AME behaves differently in the in vitro 
system. PpIX induced by it in the cells is far more than 
produced by ALA in the cells. This is not the case in the in 
vivo animal study that received the AME IV. The difference 
observed in the in vitro and the IV in vivo systems may be 
attributed to drug metabolism in the in vivo system that 
reduced the drug availability of the parent compound AME 
to produce PpIX. However, in an in vivo system with the 
topical application of AME (which mimics the in vitro system) 
allows for the longer retention of drug, which is bound to the 
cell membrane. This discrepancy has been described in other 
studies (15,18,19). These studies suggest that ALA derivatives 
With many carbon atoms which are highly lipid soluble might 
not be converted to ALA by enzymes because such ALA 
would accumulate at the cell membranes. and not diffuse into 
the cell. The properties of ALA would determine which ALA 
derivative induces high level of PpIX. The other variable that 
has an effect on the PpIX production is the availability of 
oxygen. In in vitro studies the oxygen pressure is sufficient 
for the conversion of ALA derivatives into PpIX. Whereas 
in an in vivo system where the oxygen tension is low, the 
build up of PpIX is expected to be lower (19). When adjacent 
skin was analysed for PpIX fluorescence using the topical 
application, it was found that the AME induced less cutaneous 
sensitivity when compared to ALA. 
Thus, there are merits for ALA and AME delivery via 
topical applications. This delivery system may take many 
forms such as rinses, gels or creams, which have to be 
constituted extemporaneously when needed due to instability 
of ALA. Films prepared for this study can be made and stored 
in an airtight container at room temperature for 3 to 6 
months. These topical applications also have muco-adhesive 
properties and can be good candidates for use in the oral 
cavity PDD and PDT. However, oral rinses require the 
patient to continuously rinse for 20 min. Hence oral rinses 
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are not practical for routine clinical use. Also the contact 
time for ALA on oral tissue is short with the use of an oral 
rinse. 
Despite the expected differences in the availability of ALA 
in the Gantrez application and PVP application, their in vivo 
performances did not show significant differences. This 
indicates that the rate-limiting step of ALA delivery to the 
tumour tissue was the transdermal transport of the hydrophilic 
ALA compound. However this seems to be tumour dependent 
(13). 
Our study concludes that the amount of PpIX produced, 
as a function of time (1-6 h) in the in vivo system does not 
correspond to the in vitro system. While topical applications 
will be good for accessible tumours, as the TIN differential is 
significant by 3 h (p>0.05), intravenous administration also 
has its advantages because high tumour to normal differential 
is achieved at a shorter duration for both ALA and AME. 
Between the intravenous administration and the topical 
application, the difference lies in the fact that there is low 
systemic uptake in the topical application. Therefore the mode 
of ALA and AME administration will play an important role 
in the specific application in cancer diagnosis of the bladder. 
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